SCHEMBL246273

SCHEMBL246273

CCOC(=O)C(=NNC)C(=O)OCC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 1/20 0.49
MAPT P10636 3/20 0.48
GAA P10253 2/20 0.42
MGAM O43451 1/20 0.42
SI P14410 1/20 0.42
MGAM2 Q2M2H8 1/20 0.42
EGLN1 Q9GZT9 1/20 0.41
ALDH1A1 P00352 6/20 0.40
NPSR1 Q6W5P4 1/20 0.39
GLO1 Q04760 1/20 0.39
LMNA P02545 2/20 0.39
HSD17B10 Q99714 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
CYP2D6 P10635 1/20 0.38
TSHR P16473 1/20 0.38
ALOX15 P16050 1/20 0.37
SOAT1 P35610 1/20 0.37
MAPK1 P28482 1/20 0.36
KCNH2 Q12809 1/20 0.36
TRPA1 O75762 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27850545 0.90 MAPT (0.44) ABCB1MAPTGAAMGAMSI
SCHEMBL14971063 0.88 MAPT (0.43) ABCB1MAPTGAAMGAMSI
SCHEMBL22642271 0.83 MAPT (0.40) ABCB1MAPTGAAMGAMSI
SCHEMBL13901633 0.82 MAPT (0.48) ABCB1MAPTGAAMGAMSI
SCHEMBL25703933 0.80 MAPT (0.68) ABCB1MAPTGAAMGAMSI
SCHEMBL388339 0.80 MAPT (0.68) ABCB1MAPTGAAMGAMSI
SCHEMBL388338 0.80 MAPT (0.68) ABCB1MAPTGAAMGAMSI
SCHEMBL23771890 0.78 MAPT (0.46) ABCB1MAPTGAAMGAMSI
SCHEMBL19558883 0.78 MAPT (0.46) ABCB1MAPTGAAMGAMSI
SCHEMBL4693411 0.78 MAPT (0.46) ABCB1MAPTGAAMGAMSI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3377470-B1 PROCESS FOR THE SYNTHESIS OF INTERMEDIATES USEFUL FOR PREPARING 1,3,4-TRIAZINE DERIVATIVES FMC CORP (US) 2020-11-11 EP claimed
US-10294196-B2 Process for the synthesis of intermediates useful for preparing 1,3,4-triazine derivatives FMC CORP (US) 2019-05-21 US claimed
US-20180334427-A1 Process for the Synthesis of Intermediates Useful for Preparing 1,3,4-Triazine Derivatives FMC CORP (US) 2018-11-22 US claimed
EP-3377470-A1 PROCESS FOR THE SYNTHESIS OF INTERMEDIATES USEFUL FOR PREPARING 1,3,4-TRIAZINE DERIVATIVES FMC Corporation (US) 2018-09-26 EP claimed
EP-3377470-B1 PROCESS FOR THE SYNTHESIS OF INTERMEDIATES USEFUL FOR PREPARING 1,3,4-TRIAZINE DERIVATIVES FMC CORP (US) 2020-11-11 EP disclosed
CN-105198861-B 6- acyl group -1,2,4- triazine -3,5- derovatives and herbicide FMC公司 2019-11-22 CN disclosed
US-10294196-B2 Process for the synthesis of intermediates useful for preparing 1,3,4-triazine derivatives FMC CORP (US) 2019-05-21 US disclosed
US-10294196-B2 Process for the synthesis of intermediates useful for preparing 1,3,4-triazine derivatives FMC CORP (US) 2019-05-21 US disclosed
US-10294196-B2 Process for the synthesis of intermediates useful for preparing 1,3,4-triazine derivatives FMC CORP (US) 2019-05-21 US disclosed
EP-3317267-B1 PYRIDAZINONES AS HERBICIDAL COMPOUNDS SYNGENTA PARTICIPATIONS AG (CH) 2019-05-08 EP disclosed
US-20190047968-A1 6-ACYL-1,2,4-TRIAZINE-3,5-DIONE DERIVATIVE AND HERBICIDES FMC CORP (US) 2019-02-14 US disclosed
US-20180334427-A1 Process for the Synthesis of Intermediates Useful for Preparing 1,3,4-Triazine Derivatives FMC CORP (US) 2018-11-22 US disclosed
WO-2009074827-A2 COMBINATION COMPRISING A MEK INHIBITOR AND AN AURORA KINASE INHIBITOR 188 ASTRAZENECA AB (SE) 2009-06-18 WO disclosed
WO-2009050506-A2 COMBINATION 059 ASTRAZENECA AB (SE) 2009-04-23 WO disclosed
US-20090099174-A1 COMBINATION 059 ASTRAZENECA AB (SE) 2009-04-16 US disclosed
US-20080280957-A1 Heterocyclic Inhibitors of Mek and Methods of Use Thereof ARRAY BIOPHARMA, INC. (US) 2008-11-13 US disclosed
WO-2008120004-A1 COMBINATION OF A MEK- INHIBITOR AND A B-RAF INHIBITOR FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2008-10-09 WO disclosed
EP-1967516-A1 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamide derivatives as MEK inhibitors for the treatment of hyperproliferative diseases Array Biopharma, Inc. (US) 2008-09-10 EP disclosed
EP-1922307-A2 HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF Array Biopharma, Inc. (US) 2008-05-21 EP disclosed
WO-2007044084-A2 HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC. (US) 2007-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099174-A1 COMBINATION 059 MTOR, RICTOR, MAPK9 ABCB1 496/4885MAPT 4324/4885GAA 1659/4885
US-20080280957-A1 Heterocyclic Inhibitors of Mek and Methods of Use Thereof BRAF, NRAS, MAP3K1 ABCB1 2595/4885MAPT 4461/4885GAA 2860/4885
US-10294196-B2 Process for the synthesis of intermediates useful for preparing 1,3,4-triazine derivatives DAZAP1, TALDO1, GMDS ABCB1 4437/4885MAPT 3377/4885GAA 1833/4885
US-20190047968-A1 6-ACYL-1,2,4-TRIAZINE-3,5-DIONE DERIVATIVE AND HERBICIDES DDT, AADAC, DAZAP1 ABCB1 2984/4885MAPT 3711/4885GAA 657/4885
US-20180334427-A1 Process for the Synthesis of Intermediates Useful for Preparing 1,3,4-Triazine Derivatives DHPS, CYP4Z1, NISCH ABCB1 4082/4885MAPT 3178/4885GAA 2796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.